{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:13:37Z","timestamp":1788408817445,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00462-8","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:26:06Z","timestamp":1783873566000},"page":"265-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update?"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-3901","authenticated-orcid":false,"given":"Diona","family":"Gjermeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"issue":"16","key":"462_CR1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072PubMedPMID:33825853;PubMedCentralPMCID:PMC8060056","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072PubMedPMID:33825853;PubMedCentralPMCID:PMC8060056.","journal-title":"Eur Heart J"},{"key":"462_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.11.003","author":"S Dorbala","year":"2025","unstructured":"Dorbala S, Adigun R, Alexander KM, Brambatti M, Cuddy SAM, Dispenzieri A, et al. Development of imaging endpoints for clinical trials in AL and ATTR amyloidosis: proceedings of the amyloidosis forum. JACC Cardiovasc Imaging. 2025. https:\/\/doi.org\/10.1016\/j.jcmg.2024.11.003.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"20","key":"462_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","volume":"16","author":"D Delgado","year":"2025","unstructured":"Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D, et al. Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis. 2025;16(20):29. https:\/\/doi.org\/10.1186\/s13023-025-03547-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"462_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"2","key":"462_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2305434.","journal-title":"N Engl J Med"},{"issue":"16","key":"462_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"462_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"37","key":"462_CR8","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"4","key":"462_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: Cardiooncology state-of-the-art review. JACC CardioOncology. 2021;3(4):488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006.","journal-title":"JACC CardioOncology"},{"key":"462_CR10","unstructured":"2023 ESC Guidelines for the management of cardiomyopathies | European Heart Journal | Oxford Academic. [cited 2024 Nov 5]. https:\/\/academic.oup.com\/eurheartj\/article\/44\/37\/3503\/7246608?login=true."},{"issue":"2","key":"462_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","volume":"26","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Concei\u00e7\u00e3o I, et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024;26(2):397\u2013410. https:\/\/doi.org\/10.1002\/ejhf.3138.","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"462_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2300757.","journal-title":"N Engl J Med"},{"key":"462_CR13","doi-asserted-by":"publisher","unstructured":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation. [cited 2024 Nov 5]. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","DOI":"10.1161\/CIR.0000000000001063"},{"issue":"9","key":"462_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137(9):961\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033502.","journal-title":"Circulation"},{"issue":"12","key":"462_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"19","key":"462_CR16","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/eurheartj\/ehag069","volume":"47","author":"MJ Krantz","year":"2026","unstructured":"Krantz MJ, Senatore F, Psotka MA, Fiuzat M, Southworth MR, Stockbridge N. Heart failure endpoints in Food and Drug Administration pivotal trials. Eur Heart J. 2026;47(19):2245\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehag069.","journal-title":"Eur Heart J"},{"issue":"148","key":"462_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","volume":"1","author":"AB Miller","year":"2021","unstructured":"Miller AB, Januzzi JL, O\u2019Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, et al. Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial [ATTR-ACT]). Am J Cardiol. 2021;1(148):146\u201350. https:\/\/doi.org\/10.1016\/j.amjcard.2021.02.035.","journal-title":"Am J Cardiol"},{"issue":"10","key":"462_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","volume":"85","author":"DP Judge","year":"2025","unstructured":"Judge DP, Alexander KM, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs SDJ, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2025;85(10):1003\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.042.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"462_CR19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021;128(10):1554\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318187.","journal-title":"Circ Res"},{"key":"462_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.24725","author":"P Sandroni","year":"2016","unstructured":"Sandroni P. Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol. 2016. https:\/\/doi.org\/10.1002\/ANA.24725.","journal-title":"Ann Neurol"},{"issue":"7","key":"462_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, Maurer MS, Gillmore JD, Bender S, Aldinc E, Eraly SA, et al. Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial. J Am Coll Cardiol. 2025;85(7):753\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.015.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"462_CR22","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jacc.2024.10.097","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, Maurer MS, Gillmore JD, Bender S, Jay PY, Solomon SD. Worsening of heart failure in outpatients with transthyretin amyloidosis and cardiomyopathy in the APOLLO-B trial. J Am Coll Cardiol. 2025;85(7):744\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.097.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"462_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jjcc.2024.03.008","volume":"84","author":"G Bazoukis","year":"2024","unstructured":"Bazoukis G, Saplaouras A, Efthymiou P, Yiannikourides A, Liu T, Sfairopoulos D, et al. Atrial fibrillation in the setting of cardiac amyloidosis\u2014a review of the literature. J Cardiol. 2024;84(3):155\u201360. https:\/\/doi.org\/10.1016\/j.jjcc.2024.03.008.","journal-title":"J Cardiol"},{"issue":"Supplement_1","key":"462_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.0766","volume":"42","author":"M Murthi","year":"2021","unstructured":"Murthi M, Sharma B, Velagapudi S, Atluri R, Velazquez G, Wahab A. In hospital mortality and outcomes of patients with acute decompensated diastolic heart failure with and without amyloidosis. Eur Heart J. 2021;42(Supplement_1):ehab724.0766. https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.0766.","journal-title":"Eur Heart J"},{"issue":"4","key":"462_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/13506120903421538","volume":"16","author":"S Lehrke","year":"2009","unstructured":"Lehrke S, Steen H, Kristen AV, Merten C, Lossnitzer D, Dengler TJ, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2009;16(4):187\u201395. https:\/\/doi.org\/10.3109\/13506120903421538.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"6","key":"462_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","volume":"15","author":"MS Maurer","year":"2022","unstructured":"Maurer MS, Dunnmon P, Fontana M, Quarta CC, Prasad K, Witteles RM, et al. Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group. Circ Heart Fail. 2022;15(6):e009038. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009038.","journal-title":"Circ Heart Fail"},{"issue":"14","key":"462_CR27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","volume":"83","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. J Am Coll Cardiol. 2024;83(14):1276\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.036.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"462_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010661","volume":"16","author":"PW Armstrong","year":"2023","unstructured":"Armstrong PW, Zheng Y, Lund LH, Butler J, Troughton RW, Emdin M, et al. Evolution of NT-proBNP during prerandomization screening in VICTORIA: implications for clinical outcomes and efficacy of vericiguat. Circ Heart Fail. 2023;16(10):e010661. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010661.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"462_CR29","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/ejhf.3540","volume":"27","author":"L Zeldin","year":"2025","unstructured":"Zeldin L, Eichler JBS, Teruya SL, Weinsaft AY, Mirabal A, Cuomo MO, et al. Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2025;27(12):2961\u201370. https:\/\/doi.org\/10.1002\/ejhf.3540.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"462_CR30","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ejhf.3339","volume":"26","author":"SA Muller","year":"2024","unstructured":"Muller SA, Peir\u00f3-Aventin B, Biagioni G, Tini G, Saturi G, Kronberger C, et al. Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024;26(9):2025\u201334. https:\/\/doi.org\/10.1002\/ejhf.3339.","journal-title":"Eur J Heart Fail"},{"key":"462_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2024.101948","author":"P Soman","year":"2024","unstructured":"Soman P, Garcia-Pavia P, Gillmore JD, Adams D, Conceicao I, Coelho T, et al. Rationale & design of ACT-EARLY, the acoramidis transthyretin amyloidosis prevention trial: early detection using cardiac radionuclide imaging. J Nucl Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.101948.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"462_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00462-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00462-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00462-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:24:16Z","timestamp":1788405856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00462-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00462-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Diona Gjermeni reports research support by a grant from German Research Foundation. Kevin M. Alexander has received consulting fees from Alexion, Alnylam, Arbor Biotechnologies, Bayer, BridgeBio, Novo Nordisk, and Pfizer; James Januzzi is supported in part by the Adolph Hutter professorship and has received research grants from Abbott Diagnostics, Applied Therapeutics, AstraZeneca, HeartFlow, and Novartis; he has received consulting fees\/honorarium from Abbott, AstraZeneca, Beckman-Coulter, Boehringer-Ingelheim, Bristol-Myers, Intellia, Jana Care, Novartis, Pfizer, Merck, Roche Diagnostics and Siemens; He participates on data safety monitoring boards or endpoint committees for Abbott, AbbVie, Bayer, CVRx, Pfizer, Roche Diagnostics and Takeda and reports equity holdings in Imbria Pharmaceuticals and Jana Care. James L. Januzzi does not report relevant conflicts of interest with this work. Kenneth W. Mahaffey\u2019s financial disclosures can be viewed at\n                      \n                      . Kenneth W. Mahaffey and Kevin M. Alexander are board members of\u00a0\n                      Cardiology\u00a0and\u00a0Therapy\n                      and were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies\u00a0and\u00a0does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}